This content is from: Capital Markets

Senate to ignore OTC regulatory arbitrage

Despite recent fears that the US and Europe are diverging on OTC derivatives regulation, the US Senate is unlikely to consider the prospect of regulatory arbitrage when legislating

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an IFLR subscriber? Login here

Instant access to all of our content. Membership Options | 30 Day Trial